Application of interleukin-4 and its genes for biotherapy of brain malignant gliomas
Keywords:
malignant glioma, interleukin-4, immunotoxins gene therapy gliomaAbstract
Information about biological attitudes of interleukin-4, experimental treatment of brain malignant tumours on the base of researching interleukin-4 influence in gliomas immunobiology is provided. Scientific data about using interleukin-4 inimmunotoxins while gliomas treatment, about animals viability after interleukin-4 gene transfection in glioma cells and about results of experimental gliomas treatment with non-gliomas cells transfected with interleukin-4 gene are presented.
References
Бережная Н.М.,Чехун В.Ф. Система интерлейкинов и рак. — К.: ДИА, 2000–224с.
Витковский Ю.А. Влияние интерлейкина-4 на систему гомеостаза ин витро // Иммунология.— 2001.— №1.— С.43–46.
Возианов А.Ф., Бутенко А.К., Зак К.П. Цитокины: биологические и противоопухолевые свойства. — К.: Наук. думка,1998.— С.44–57.
Benedetti S., Pirola B., Poliani P.L. et al. Dexametasone ingibits the anti-tumor effect of interleukin-4 on rat experimental gliomas // Gene Ther.— 2003— N2.— P.188–192.
Benedetti S., Pirola B., Pollo B. et al. Gene therapy of experimental brain tumors using neurals progenitor cells // Gene Ther.–2000.— N4. — P.447–450.
Hall W.A.Target toxin therapy for malignant astrocytoma // Neurosurgery.–2000.— V.46, N3. — P.544–551.
Iwasaki K., Rogers L.R., Estes M.L., Barna B.P. Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-alpha and/or interferon-gamma // Neurosurgery.–1993.—V.33, N3.—P.493–494.
Joshi B.H., Leland P., Asher A. et al. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures // Cancer Res.— 2001.— V.61, N22.—P.8058–8061.
Joshi B.H., Leland P., Silber J. et al. IL-4 receptors on human medulloblastoma tumor serve as a sensitive target for a circular permitted IL-4- Pseudomonas exotoxin fusion protein // Brit. J.Cancer.–2002. — V.86, N2.—P.285–291.
Kawakami K., Kawakami M., Puri R.K. Overexpressed cell surface interleukin-4 receptor molekules can be successfully target for antitumor cytotoxin therapy // Crit.Rev.Immunol.–2001.— V.21, N1–3.—P.299–310.
Lumniczky E., Desaknai S., Mangel L. et al. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model //Cancer Gene Ther.–2000.— V.9, N1.—P.44–52.
Okada H., Giezeman-Smits K.M., Tahara H. et al. Effective cytotoxine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine // Gene Ther.–1999. — V.6, N2.—P.219–226.
Okada H., Pollack I.F., Lotze M.T. et al. Gene therapy of malignant gliomas : a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response // Hum. Gene Ther.–2000. — V.11, N4.—P.637–653.
Okada H., Villa L., Atanuci J. et al. Cytokine gene therapy of gliomas : effective induktion of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells // Gene Ther.–2001.— V.8, N15.—P.1157–1166.
Puri R.K. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors // Methods Mol.Biol.–2001.—V.166.—P.155–176.
Puri R.K., Leland P., Kreitman R.J., Pastan I. Human neurogical cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL-4-Pseudomonas exotoxin chimeric protein // Int.J.Cancer.–1994.— V.58, N4.—P.574–581.
Puri R.K., Hoon D.S., Leland P. et al. Preclinical development of a recombinant toxin containing circularly permitted interleukin-4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma // Cancer Res.–1996.— V.56, N24.—P.5631–5637.
Rand R.W., Kreitman R.J., Patronas N. et al.Intratumoral administration of recombinant circularly permitted interleukin-4- Pseudomonas exotoxin in patients with high-grade glioma // Clin.Cancer Res.–2000. —V.6, N6.—P.2157–2165.
Saleh M., Davis I.D., Wilks A.P. The paracrine role of tumor-derived mIL-4 on tumor-associated endothelium // Int.J.Cancer. — 1997.— V.72, N4.—P.664–672.
Saleh M., Wiegms A., Malone Q. et al. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors // Int.J.Cancer.— 1999.— V.91, N5.—P.438–445.
Tseng S.N., Hwang L.N., Lin S.M. Induction of anti tumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines // J.Immunother. –1997.—V.20, N5.—P.334–342.
Vyas B.,Vukmanovic-Stejic M., Noble A., Remeny D. Biology of inflammatory products : cytokines and mediators // Inter.Arch. Allergy Immunol.–1999.—V.118, N2–4.—P.433–436.
Wei M.X., Li F., Gaudlie J., Chiocca E.A. Effects on brain tumor cell proliferation adenovirus vector that bears the interleukin-4 gene // Neurovirology.— 1998.—N2.—P.237–241.
Wei M.X., Tamiya T., Hurford R.K. et al. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer // Hum.Gene Ther.–1995.—V.6, N4.—P.437–443.
Wigmore S.J., Maingay J.P., Frearon K.C. et al. Effect of interleukin-4 on proinflammatory cytokine production and the acute phase response in healthy individuals and in patients with cancer or multiple organ failure // Clin. Sci.–1998.—V.95, N3.—P.347–354.
Xing B., Ren Z., Su C. Experimental study of interleukin-4 gene therapy for glioma // Zhonghus Zhong Liu Za Zhi.–1999.—V.21, N1.—P.13–15.
Yoshikawa K., Kajiwara R., Ideguchi M. et al. Immune gene therapy of experimental mouse brain tumor with adenovirus-mediated gene transfer of murine interleukine-4 // Cancer Immunol. Immunother.–2000.— V.49, N1.—P.23–33.
Yu J.S., Wei M.X., Chioca E.A. et al. Treatment of glioma by engeneered interleukin-4-secreting cells // Cancer Res. — 1993.— V.53, N13.—P.3125–3128.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2004 N. I. Lysyany, O. V. Markova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.
